Literature DB >> 17470806

Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Chaohong Sun1, Danying Song, Rachel A Davis-Taber, Leo W Barrett, Victoria E Scott, Paul L Richardson, Ana Pereda-Lopez, Marie E Uchic, Larry R Solomon, Marc R Lake, Karl A Walter, Philip J Hajduk, Edward T Olejniczak.   

Abstract

The pituitary adenylate cyclase-activating polypeptide (PACAP) receptor is a class II G protein-coupled receptor that contributes to many different cellular functions including neurotransmission, neuronal survival, and synaptic plasticity. The solution structure of the potent antagonist PACAP (residues 6'-38') complexed to the N-terminal extracellular (EC) domain of the human splice variant hPAC1-R-short (hPAC1-R(S)) was determined by NMR. The PACAP peptide adopts a helical conformation when bound to hPAC1-R(S) with a bend at residue A18' and makes extensive hydrophobic and electrostatic interactions along the exposed beta-sheet and interconnecting loops of the N-terminal EC domain. Mutagenesis data on both the peptide and the receptor delineate the critical interactions between the C terminus of the peptide and the C terminus of the EC domain that define the high affinity and specificity of hormone binding to hPAC1-R(S). These results present a structural basis for hPAC1-R(S) selectivity for PACAP versus the vasoactive intestinal peptide and also differentiate PACAP residues involved in binding to the N-terminal extracellular domain versus other parts of the full-length hPAC1-R(S) receptor. The structural, mutational, and binding data are consistent with a model for peptide binding in which the C terminus of the peptide hormone interacts almost exclusively with the N-terminal EC domain, whereas the central region makes contacts to both the N-terminal and other extracellular parts of the receptor, ultimately positioning the N terminus of the peptide to contact the transmembrane region and result in receptor activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470806      PMCID: PMC1876540          DOI: 10.1073/pnas.0611397104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  7TM receptors: the splicing on the cake.

Authors:  G J Kilpatrick; F M Dautzenberg; G R Martin; R M Eglen
Journal:  Trends Pharmacol Sci       Date:  1999-07       Impact factor: 14.819

2.  Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.

Authors:  A Vandermeers; S Vandenborre; X Hou; P de Neef; P Robberecht; M C Vandermeers-Piret; J Christophe
Journal:  Eur J Biochem       Date:  1992-09-15

3.  Protein backbone angle restraints from searching a database for chemical shift and sequence homology.

Authors:  G Cornilescu; F Delaglio; A Bax
Journal:  J Biomol NMR       Date:  1999-03       Impact factor: 2.835

4.  Presynaptic localization of the PACAP-typeI-receptor in hippocampal and cerebellar mossy fibres.

Authors:  C Otto; W Zuschratter; P Gass; G Schütz
Journal:  Brain Res Mol Brain Res       Date:  1999-03-20

5.  An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule.

Authors:  Z X Wang
Journal:  FEBS Lett       Date:  1995-02-27       Impact factor: 4.124

Review 6.  VIP and PACAP: very important in pain?

Authors:  T Dickinson; S M Fleetwood-Walker
Journal:  Trends Pharmacol Sci       Date:  1999-08       Impact factor: 14.819

7.  Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells.

Authors:  Hideki Kato; Atsushi Ito; Jun Kawanokuchi; Shijie Jin; Tetsuya Mizuno; Kosei Ojika; Ryuzou Ueda; Akio Suzumura
Journal:  Mult Scler       Date:  2004-12       Impact factor: 6.312

8.  Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding.

Authors:  P Gaudin; A Couvineau; J J Maoret; C Rouyer-Fessard; M Laburthe
Journal:  Biochem Biophys Res Commun       Date:  1995-06-26       Impact factor: 3.575

9.  Tunable alignment of macromolecules by filamentous phage yields dipolar coupling interactions.

Authors:  M R Hansen; L Mueller; A Pardi
Journal:  Nat Struct Biol       Date:  1998-12

10.  Stereospecific nuclear magnetic resonance assignments of the methyl groups of valine and leucine in the DNA-binding domain of the 434 repressor by biosynthetically directed fractional 13C labeling.

Authors:  D Neri; T Szyperski; G Otting; H Senn; K Wüthrich
Journal:  Biochemistry       Date:  1989-09-19       Impact factor: 3.162

View more
  58 in total

Review 1.  Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.

Authors:  Kuntal Pal; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

2.  Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain.

Authors:  Martine Prévost; Pascale Vertongen; Vincent Raussens; David Jonathan Roberts; Johnny Cnudde; Jason Perret; Magali Waelbroeck
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 4.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1.

Authors:  Augen A Pioszak; Naomi R Parker; Kelly Suino-Powell; H Eric Xu
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

6.  Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Patrick M Sexton; Ruben Abagyan; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2008-05-08       Impact factor: 4.436

7.  Biological and structural analysis of truncated analogs of PACAP27.

Authors:  Steve Bourgault; David Vaudry; Laure Guilhaudis; Emilie Raoult; Alain Couvineau; Marc Laburthe; Isabelle Ségalas-Milazzo; Hubert Vaudry; Alain Fournier
Journal:  J Mol Neurosci       Date:  2008-05-13       Impact factor: 3.444

8.  Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.

Authors:  Laurence J Miller; Quan Chen; Polo C-H Lam; Delia I Pinon; Patrick M Sexton; Ruben Abagyan; Maoqing Dong
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

Review 9.  Biophysical characterization of G-protein coupled receptor-peptide ligand binding.

Authors:  David N Langelaan; Pascaline Ngweniform; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2011-04       Impact factor: 3.626

10.  PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Authors:  Terry W Moody; Lingaku Lee; Tatiana Iordanskaia; Irene Ramos-Alvarez; Paola Moreno; Howard E Boudreau; Thomas L Leto; Robert T Jensen
Journal:  Peptides       Date:  2018-09-28       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.